eligibility_summary
Eligible: adults 18–70 with histologic/cytologic lung adenocarcinoma, post-lobectomy with lymph node dissection, pathologic stage IIIA (IASLC 8th), received standard platinum-based adjuvant therapy or none, have dynamic tumor biomarkers, consent to 3-year follow-up. Exclude: other histologies, no surgery, stages I/II/IIIB–IV, recent trials (<4 wks), substance abuse, pregnant/breastfeeding, immune/autoimmune disease or on immunosuppressants/hormones, prohibitive comorbidities, unavailable for follow-up.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II single-arm adjuvant trial in post-resection stage IIIA lung adenocarcinoma testing a personalized Neoantigen Tumor Vaccine (biological cancer vaccine). Mechanism: patient-specific tumor neoantigens are given subcutaneously to load antigen-presenting cells (primarily dendritic cells), promote MHC I/II presentation, and expand tumor-specific T cells—CD8+ cytotoxic and CD4+ helper—aiming to clear residual micrometastatic disease and establish immune memory. Targets: neoantigen-bearing tumor cells, immune cells/pathways include dendritic cell antigen presentation, TCR recognition of neoantigens, clonal T-cell expansion, and cytotoxic effector pathways (perforin/granzyme).